Page contentsKey factsDecisionRelated contentKey facts Invented name Pelgraz Active Substance pegfilgrastim Therapeutic area Haematology-Hemostaseology Decision number P/0206/2021 PIP number EMEA-002671-PIP02-20 Pharmaceutical form(s) Solution for injection in pre-filled syringe Condition(s) / indication(s) Prevention of chemotherapy-induced febrile neutropeniaTreatment of chemotherapy-induced neutropenia Route(s) of administration Subcutaneous use Contact for public enquiries Accord Healthcare S.L.U.E-mail: regulatory_EU@accord-healthcare.comTel. +34 933010064 Decision type P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) Decision date 10/05/2021DecisionP/0206/2021 : EMA decision of 10 May 2021 on the agreement of a paediatric investigation plan for pegfilgrastim (Pelgraz), (EMEA-002671-PIP02-20)AdoptedReference Number: EMA/245270/2021 English (EN) (242 KB - PDF)First published: 11/02/2022ViewRelated contentPelgrazShare this page